NCT05456373: Intraoperative Use of ClearEdge Device in Breast Conserving Surgery

NCT05456373
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Not Applicable
Drug Category: Other

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must be suitable for a lumpectomy procedure
Exclusions: Patients currently receiving chemotherapy
https://ClinicalTrials.gov/show/NCT05456373

Comments are closed.

Up ↑